CAMPANI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.174
AS - Asia 3.072
EU - Europa 2.678
SA - Sud America 396
Continente sconosciuto - Info sul continente non disponibili 127
AF - Africa 91
OC - Oceania 41
Totale 10.579
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.056
RU - Federazione Russa 1.031
CN - Cina 1.004
SG - Singapore 844
IT - Italia 829
HK - Hong Kong 317
KR - Corea 310
BR - Brasile 300
VN - Vietnam 226
IE - Irlanda 149
FR - Francia 120
FI - Finlandia 96
SE - Svezia 96
DE - Germania 93
GB - Regno Unito 83
IN - India 80
CA - Canada 79
BD - Bangladesh 68
PL - Polonia 68
JO - Giordania 48
ID - Indonesia 47
NL - Olanda 44
AU - Australia 41
AR - Argentina 34
JP - Giappone 20
IQ - Iraq 19
CO - Colombia 15
ZA - Sudafrica 15
EC - Ecuador 13
NG - Nigeria 13
RO - Romania 13
TR - Turchia 13
UZ - Uzbekistan 13
ES - Italia 12
CI - Costa d'Avorio 10
MX - Messico 10
PK - Pakistan 10
UA - Ucraina 10
EG - Egitto 9
VE - Venezuela 9
PE - Perù 8
PY - Paraguay 8
CR - Costa Rica 7
KE - Kenya 7
NP - Nepal 7
BJ - Benin 6
CL - Cile 6
DZ - Algeria 6
HN - Honduras 6
JM - Giamaica 6
MA - Marocco 6
PH - Filippine 6
AT - Austria 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
IL - Israele 4
OM - Oman 4
SA - Arabia Saudita 4
TW - Taiwan 4
AM - Armenia 3
CH - Svizzera 3
RS - Serbia 3
TH - Thailandia 3
AL - Albania 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
EE - Estonia 2
GT - Guatemala 2
HU - Ungheria 2
KG - Kirghizistan 2
MY - Malesia 2
SC - Seychelles 2
SI - Slovenia 2
SN - Senegal 2
SV - El Salvador 2
UY - Uruguay 2
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GN - Guinea 1
GR - Grecia 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
MG - Madagascar 1
MM - Myanmar 1
MT - Malta 1
MU - Mauritius 1
MZ - Mozambico 1
Totale 10.442
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.047
Singapore 669
Ashburn 652
Hefei 402
Seoul 308
Hong Kong 276
San Jose 235
Dublin 149
Milan 143
Council Bluffs 123
Beijing 114
Los Angeles 109
Florence 102
Ho Chi Minh City 94
Chandler 71
Fairfield 70
Moscow 70
Rome 66
Buffalo 63
Warsaw 63
Kent 60
Helsinki 56
New York 54
Lauterbourg 51
Hanoi 50
Altamura 42
Lawrence 41
Munich 41
Phoenix 41
The Dalles 40
London 39
Shanghai 39
Melbourne 38
Houston 37
Jakarta 36
Paris 30
Chicago 29
Dallas 29
Cambridge 28
São Paulo 28
Bengaluru 25
Woodbridge 24
Arezzo 23
Bologna 23
Lappeenranta 23
Princeton 23
Boston 22
Naples 22
Seattle 22
Wilmington 22
Boardman 21
Mumbai 21
Atlanta 19
Frankfurt am Main 17
Turku 16
Brooklyn 14
Tokyo 14
Toronto 14
Turin 14
West Jordan 14
Abuja 13
Amman 13
Montreal 13
Orem 12
Washington 12
Genoa 11
Haiphong 11
Queens 11
Rio de Janeiro 11
Abidjan 10
City of London 10
San Diego 10
Ann Arbor 9
Chennai 9
Newark 9
Philadelphia 9
St Louis 9
Tashkent 9
Timisoara 9
Da Nang 8
Hangzhou 8
Miami 8
Nuremberg 8
Porto Alegre 8
Riverside 8
Amsterdam 7
Buenos Aires 7
Denver 7
Guangzhou 7
Medford 7
Miano 7
Modena 7
Parma 7
Piscataway 7
Redondo Beach 7
Bari 6
Belo Horizonte 6
Cotonou 6
Figino 6
Istanbul 6
Totale 6.376
Salva come PNG Salva come JPEG
Nome #
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 289
Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis 252
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 237
A large rheumatoid nodule mimicking hepatic malignancy 230
Circulating biomarkers of response to systemic treatments in advanced hepatocellular 228
Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives 222
Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives 216
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 212
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma 206
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort survey 204
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 200
Practical insights into chronic management of hepatic Wilson's disease 198
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center 196
Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma 196
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 196
CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib 190
Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells 189
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients 186
Metabolic disorders across hepatocellular carcinoma in Italy 184
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma 183
Transjugular intrahepatic Porto-systemic shunt positively influences the composition and metabolic functions of the gut microbiota in cirrhotic patients 169
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 168
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 164
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 164
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 163
The changing scenario of hepatocellular carcinoma in Italy: an update 163
Main factors influencing long-term outcomes of liver transplantation in 2022 161
An atypical case of palmo-plantar erythrodysesthesia related to cabozantinib 160
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib 158
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 155
The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma 155
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma 154
Pattern of macrovascular invasion in hepatocellular carcinoma 153
Needs evaluation questionnaire for liver disease: a novel assessment of unmet needs in patients with chronic liver disease 150
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 150
Quick and easy assessment of sarcopenia in cirrhosis: Can ultrasound be the solution? 148
Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma 146
Fragility index of positive phase II and III randomized clinical trials of treatments for hepatocellular carcinoma (2002-2022) 144
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC 142
Prevalence of nutritional risk and malnutrition during and after hospitalization for COVID-19 infection: Preliminary results of a single-centre experience 142
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab 141
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab 140
No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC 139
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 137
Time-varying mHAP III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization 137
Elusive Hepatic Nodules 133
Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs 132
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 129
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab 127
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA 127
Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver 127
Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes 126
Biological therapies in patients with liver disease: are they really lifesavers? 126
Systemic treatment of hepatocellular carcinoma: the times they are a-changin' 122
The upward trajectory of the UEG journal: Next Generation Trainee Editors 122
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice 115
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 113
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 110
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 107
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma 107
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors 99
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care 95
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 94
Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection 65
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab 65
Probiotics and the gut-liver axis 52
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 46
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab 29
Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma 25
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma 24
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 16
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 16
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma 15
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes 15
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data 15
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 15
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 14
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 14
Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib 12
Alcohol Plays a Detrimental Role in the Prognosis of Hepatocellular Carcinoma Related to Steatotic Liver Disease 11
null 2
Totale 10.579
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.522
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.522
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022171 0 0 0 2 2 13 0 10 31 34 32 47
2022/2023586 36 111 31 8 27 109 83 43 70 31 28 9
2023/2024669 23 39 56 18 35 71 42 198 26 71 58 32
2024/20253.230 98 310 178 447 851 458 95 131 144 93 162 263
2025/20264.634 533 704 692 415 368 158 476 187 253 255 190 403
2026/20271.025 188 302 353 182 0 0 0 0 0 0 0 0
Totale 10.579